LSR goes private in Lion Holdings takeover

- Last updated on GMT

Related tags: Stock market, Stock

US CRO Life Science Research has become a private company with the completion of its acquisition by Lion Holdings, an investment vehicle owner by CEO Andrew Baker.

The firm, which was set up to move Huntingdon Life Sciences’ financial centre to the US, delisted from the New York Stock Exchange on November 25 after shareholders approved Lion’s $8.50 per share buyout.

Like many preclinical contract research organisations (CRO), LSR has had a difficult 2009 with progressive quarterly reports dominated by falling revenues and operating income.

Related news

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars